Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry-Reference-Cited by-同舟云学术

Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry

Published:2021-04-21 Issue:10 Volume:40 Page:4039-4047
ISSN:0770-3198
Container-title:Clinical Rheumatology
language:en
Short-container-title:Clin Rheumatol

Author:

Sebastiani Marco,Venerito Vincenzo,Bugatti Serena,Bazzani Chiara,Biggioggero Martina,Petricca Luca,Foti Rosario,Bortoluzzi Alessandra,Balduzzi Silvia,Visalli Elisa,Frediani Bruno,Manfredi Andreina,Gremese Elisa,Favalli Ennio,Iannone Florenzo,Ferraccioli Gianfranco,Lapadula Giovanni,Galli Elena,Cantatore Francesco Paolo,Lomater Claudia,Atzeni Fabiola,Gorla Roberto,Fusaro Enrico,Salaffi Fausto,Conti Fabrizio,Cauli Alberto,Sarzi-Puttini Piercarlo,Carletto Antonio,Lopalco Giuseppe,

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Rheumatology

Link

https://link.springer.com/content/pdf/10.1007/s10067-021-05734-3.pdf

Reference36 articles.

1. Epstein FH, Harris ED (1990) Rheumatoid arthritis. N Engl J Med 322:1277–1289

2. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117:244–279

3. Keystone EC (2004) Safety issues related to emerging therapies for rheumatoid arthritis. Clin Exp Rheumatol 22:S148–S150

4. Lipsky PE, van der Heijde DM, St Clair EW et al (2000) Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 343:1594–1602

5. Schiff MH, von Kempis J, Goldblum R, Tesser JR, Mueller RB (2014) Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Ann Rheum Dis 73:2174–2177

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas y sintéticas dirigidas en la artritis reumatoide;Reumatología Clínica;2024-07

2. Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry;Frontiers in Medicine;2024-03-11

3. Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases;Advances in Rheumatology;2023-06-07

4. Retention of golimumab treatment following discontinuation of non‐TNF inhibitors in patients with inflammatory rheumatic diseases: An analysis of the Spanish BIOBADASER registry;Musculoskeletal Care;2021-10-19